[5-(4-bromobenzoyl)-2-phenylthiophen-3-yl]acetic acid | 875271-80-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: [5-(4-bromobenzoyl)-2-phenylthiophen-3-yl]acetic acid
• 英文别名: [5-(4-Bromobenzoyl)-2-phenylthiophene-3-yl]acetic acid；2-[5-(4-Bromobenzoyl)-2-phenylthiophen-3-yl]acetic acid；2-[5-(4-bromobenzoyl)-2-phenylthiophen-3-yl]acetic acid
• CAS: 875271-80-0
• 化学式: C₁₉H₁₃BrO₃S
• 分子量: 401.28
• InChiKey: RSPSHNZZXGZPEH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  24
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  82.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  [5-(4-bromobenzoyl)-2-phenylthiophen-3-yl]acetic acid 在 N-甲基吗啉 Kaiser oxime PS resin 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 羟胺 作用下， 以 二氯甲烷 、 氯仿 为溶剂， 生成 2-[5-(4-Bromobenzoyl)-2-phenylthiophene-3-yl]-N-hydroxyacetamide
  参考文献：
  名称：

  Serotype-selective, small-molecule inhibitors of the zinc endopeptidase of botulinum neurotoxin serotype A

  摘要：

  Botulinum neurotoxin serotype A (BoNTA) is one of the most toxic substances known. Currently, there is no antidote to BoNTA. Small molecules identified from high-throughput screening reportedly inhibit the endopeptidase-the zinc-bound, catalytic domain of BoNTA-at a drug concentration of 20 mu M. However, optimization of these inhibitors is hampered by challenges including the computational evaluation of the ability of a zinc ligand to compete for coordination with nearby residues in the active site of BoNTA. No improved inhibitor of the endopeptidase has been reported. This article reports the development of a serotype-selective, small-molecule inhibitor of BoNTA with a K-i of 12 mu M. This inhibitor was designed to coordinate the zinc ion embedded in the active site of the enzyme for affinity and to interact with a species-specific residue in the active site for selectivity. It is the most potent small-molecule inhibitor of BoNTA reported to date. The results suggest that multiple molecular dynamics simulations using the cationic dummy atom approach are useful to structure-based design of zinc protease inhibitors. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2005.08.018
• 作为产物：
  描述：

  2-Phenyl-3-thienylacetic acid 在 盐酸 、 sodium hydroxide 、 三氯化铝 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 为溶剂， 反应 8.0h， 生成 [5-(4-bromobenzoyl)-2-phenylthiophen-3-yl]acetic acid
  参考文献：
  名称：

  Serotype-selective, small-molecule inhibitors of the zinc endopeptidase of botulinum neurotoxin serotype A

  摘要：

  Botulinum neurotoxin serotype A (BoNTA) is one of the most toxic substances known. Currently, there is no antidote to BoNTA. Small molecules identified from high-throughput screening reportedly inhibit the endopeptidase-the zinc-bound, catalytic domain of BoNTA-at a drug concentration of 20 mu M. However, optimization of these inhibitors is hampered by challenges including the computational evaluation of the ability of a zinc ligand to compete for coordination with nearby residues in the active site of BoNTA. No improved inhibitor of the endopeptidase has been reported. This article reports the development of a serotype-selective, small-molecule inhibitor of BoNTA with a K-i of 12 mu M. This inhibitor was designed to coordinate the zinc ion embedded in the active site of the enzyme for affinity and to interact with a species-specific residue in the active site for selectivity. It is the most potent small-molecule inhibitor of BoNTA reported to date. The results suggest that multiple molecular dynamics simulations using the cationic dummy atom approach are useful to structure-based design of zinc protease inhibitors. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2005.08.018

文献信息

• USEFUL THIOPHENE DERIVATIVES IN THE TREATMENT OF DIABETES
  申请人：METABRAIN RESEARCH

  公开号：US20150197530A1

  公开（公告）日：2015-07-16

  The present invention relates to a thiophene derivative of the following general formula I or an enantiomer, diastereoisomer, hydrate, solvate, tautomer, racemic mixture or pharmaceutically acceptable salt thereof or to its use as a drug in particular intended for treating and/or preventing diabetes, its complications and/or associated pathologies, advantageously diabetes of type II and hyperglycemia.

  本发明涉及以下一般式I的噻吩衍生物或其对映体、二对映异构体、水合物、溶剂化合物、互变异构体、外消旋混合物或其药学上可接受的盐，以及其作为药物的用途，特别用于治疗和/或预防糖尿病、其并发症和/或相关病理，尤其是II型糖尿病和高血糖。
• SMALL-MOLECULE BOTULINUM TOXIN INHIBITORS
  申请人：Pang Yuan-Ping

  公开号：US20100260778A1

  公开（公告）日：2010-10-14

  Small-molecule inhibitors of Botulinum toxin, including BoNTA, BoNTD and BoNTE are provided, as well as methods of using the inhibitors.

  本发明提供了肉毒毒素的小分子抑制剂，包括BoNTA、BoNTD和BoNTE，以及使用这些抑制剂的方法。
• DERIVES DE THIOPHENES UTILES DANS LE TRAITEMENT DU DIABETE
  申请人：Metabrain Research

  公开号：EP2875010B1

  公开（公告）日：2016-08-31
• US9777015B2
  申请人：——

  公开号：US9777015B2

  公开（公告）日：2017-10-03
• Serotype-selective, small-molecule inhibitors of the zinc endopeptidase of botulinum neurotoxin serotype A
  作者：Jewn Giew Park、Peter C. Sill、Edward F. Makiyi、Alfonso T. Garcia-Sosa、Charles B. Millard、James J. Schmidt、Yuan-Ping Pang

  DOI：10.1016/j.bmc.2005.08.018

  日期：2006.1

  Botulinum neurotoxin serotype A (BoNTA) is one of the most toxic substances known. Currently, there is no antidote to BoNTA. Small molecules identified from high-throughput screening reportedly inhibit the endopeptidase-the zinc-bound, catalytic domain of BoNTA-at a drug concentration of 20 mu M. However, optimization of these inhibitors is hampered by challenges including the computational evaluation of the ability of a zinc ligand to compete for coordination with nearby residues in the active site of BoNTA. No improved inhibitor of the endopeptidase has been reported. This article reports the development of a serotype-selective, small-molecule inhibitor of BoNTA with a K-i of 12 mu M. This inhibitor was designed to coordinate the zinc ion embedded in the active site of the enzyme for affinity and to interact with a species-specific residue in the active site for selectivity. It is the most potent small-molecule inhibitor of BoNTA reported to date. The results suggest that multiple molecular dynamics simulations using the cationic dummy atom approach are useful to structure-based design of zinc protease inhibitors. (c) 2005 Elsevier Ltd. All rights reserved.